SCHEMBL3158144

SCHEMBL3158144

CCCCC(=O)Nc1c(C)cc(N2CCOCC2)cc1C

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.55
ALDH1A1 P00352 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
CNR1 P21554 2/20 0.54
CNR2 P34972 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.52
KDM4E B2RXH2 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
ALOX15 P16050 1/20 0.50
POLB P06746 1/20 0.50
HPGD P15428 1/20 0.50
USP2 O75604 1/20 0.49
SHMT2 P34897 1/20 0.48
KCNQ2 O43526 2/20 0.48
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2432797 0.96 CNR1 (0.58) MAPTALDH1A1MEN1KMT2ACNR1
SCHEMBL2435843 0.95 CNR1 (0.60) MAPTALDH1A1MEN1KMT2ACNR1
SCHEMBL2436162 0.95 CNR1 (0.60) MAPTALDH1A1MEN1KMT2ACNR1
SCHEMBL2438451 0.86 ALDH1A1 (0.48) MAPTALDH1A1MEN1KMT2ACNR1
SCHEMBL30795862 0.86 CNR1 (0.52) MAPTALDH1A1MEN1KMT2ACNR1
SCHEMBL2435116 0.86 CNR1 (0.52) MAPTALDH1A1MEN1KMT2ACNR1
SCHEMBL2435114 0.85 CNR1 (0.51) MAPTALDH1A1MEN1KMT2ACNR1
SCHEMBL30794573 0.85 CNR1 (0.51) MAPTALDH1A1MEN1KMT2ACNR1
SCHEMBL2437812 0.85 CNR1 (0.49) MAPTALDH1A1MEN1KMT2ACNR1
SCHEMBL2434625 0.84 ALDH1A1 (0.50) MAPTALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1947093-B9 Substituted morpholine and thiomorpholine derivatives LUNDBECK & CO AS H (DK) 2010-03-03 EP claimed
EP-1947093-B1 Substituted morpholine and thiomorpholine derivatives LUNDBECK & CO AS H (DK) 2009-09-23 EP claimed
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
EP-4580679-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS Biohaven Therapeutics Ltd. (VG) 2025-07-09 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024054807-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed
WO-2024050389-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-07 WO disclosed